fatty acids were studied in plasma, flbroblasts, erythrocytes, platelets, and leukocytes of patients affected by peroxisomal disorders such as Zellweger syndrome, X-linked adrenoleukodystrophy (X-ALD), and classic rhizomelic chondrodysplasia punctata (RCDP) and in controls. In Zellweger patients, the concentration of hexacosanoic acid (C.0) and the C26:0/C:0 ratio are greatly increased in plasma and fibroblasts. However, the plasma concentration of docosanoic acid (C:0) is greatly decreased. Also in platelets, leukocytes, and to a lesser extent erythrocytes, At least in liver and fibroblasts, the oxidation of long-chain fatty acids is believed to take place predominantly in mitochondria.
At least in liver and fibroblasts, the oxidation of long-chain fatty acids is believed to take place predominantly in mitochondria.
However, the initial chain shortening of VLCFAB via the beta-oxidation proceeds exclusively in peroxisomes rather than in mitochondria. Consequently, impairment of the peroxisomal beta-oxidation results in an accumulation of VLCFAs but not long-chain fatty acids.
At present, classification of the peroxisomal disorders is based on the degree of peroxisomal dysfunction ( Biochemical studies suggest that the VLCFA accumulation results from a deficiency of the peroxisomal VLCFA-CoA synthetase (21) (22) (23) (24) Here we report the results of our studies on the VLCFA profiles in specimens from controls and patients affected by either ZS, X-ALD, or RCDP. We analyzed VLCFA profiles not only in plasma and fibroblasts, but also in erythrocytes, platelets, and leukocytes to determine whether VLCFA analyses in blood cells could contribute to the biochemical diagnosis of these genetic disorders.
MaterIals and Methods

Patients.
Zellweger patients, X-ALD patients, and RCDP patients were diagnosed on the basis of their clinical and biochemical characteristics (1) (2) (3) (4) . Isolation of blood cells. Blood (5 mL) was sampled after an overnight fast into tubes containing sodium-EDTA, then without delay centrifuged for 10 mm at 800 x g at room temperature, thus separating the erythrocytes from the platelet-rich plasma and the buflr coat.
Erythrocytes were washed three times in isotonic NaC1 solution and centrifuged at 800 x g for 5 mm each time.
Erythrocyte
"ghosts" were isolated as described (26) and RCDP patients are summarized in Figure 2 and in However, in leukocytes from these patients the C;0 concentration was similrn-to that in the controls. 18-1.74)  1.28(0.82-1.71)  13.7 (7.0-21.1 In RCDP patients, the plasma and fibroblast concentrations of C26:0 fatty acid and the C26:0/C22:oand CJ C22.0 ratios were comparable with the control values. However, in all types of blood cells studied in this disorder, the C26:0 concentration and the C26:)/C22.Oratio were slightly greater than in the controls.
DIscussIon
We studied the concentrations of the VLCFAs in plasma, in fibroblasts, and also in blood cells of patients affected by ZS, X-ALD, or RCDP. All these disorders are peroxisomal diseases caused by a defect of one or more peroxisomal enzymes (Table 1) .
Since the early 1980s, quantification of VLCFAs in plasma and fibroblasts has been used in the biochemical diagnosis of ZS and especially X-ALD, the catabolism of VLCFAs via peroxisomal beta-oxidation being defective in both disorders (1- 4, 10, 11) . The peroxisomal system is not just a functional duplication of the mitochondrial beta-oxidation system but is involved in the chain-shortening of a distinct set of compounds that cannot be handled by the mitochondrial system, including VLCFAs. In contrast to the mitochondrial system, the activity of the peroxisomal system towards shortchain fatty acids is negligible. Figure 2 ). In erythrocytes of ZS patients, the concentration of C26:0 and the C26.0/C22.0 ratio were both only mildly but significantly increased (P = 0.01). Interestingly, the C22.0 concentrations in plasma, fibreblasts, erythrocytes, and platelets of ZS patients were significantly (P <0.001) decreased (Table 2) . No dear explanation is available for this phenomenon. In RCDP patients, no VLCFA accumulation was found either in plasma or in fibroblasts. However, concentrations of C26.0 and the C26:)/C22.0 ratios were mildly increased in erythrocytes, platelets, and leukocytes of these patients (Table 2) . Recently, Heikoop et al. (18) found that the activity of the peroxisomal beta-oxidation in fibroblasts of RCDP patients is only -50% of the control values. The abnormalities in the VLCFA profiles in the blood cells of RCDP patients probably reflect a decreased flux of VLCFAs through the peroxisomal beta-oxidation in the liver in patients affected by this disorder.
We condude that fractionation and quantification of the VLCFA, not only in plasma and fibroblasts, but also in blood cells, can contribute to the biochemical diagnosis of ZS and X-ALD.
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